We are analyzing https://link.springer.com/article/10.1186/s12916-022-02421-1.

Title:
Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer | BMC Medicine
Description:
Background The FAST study identified claudin-18 (CLDN18.2) as a promising novel therapeutic target for gastric cancer (GC). However, the tumor immune microenvironment and clinicopathological features of CLDN18.2-positive GC are unclear, making it difficult to develop and optimize CLDN18.2-targeted treatments. Methods This study included 80 GC patients, 60 of whom received anti-PD-1/PD-L1 treatment. CD4/CD8/CD20/CD66b/CD68/CD163/PD-1/PD-L1/TIM-3/LAG-3/FoxP3/CTLA-4/HLA-DR/STING, and CLDN18.2 were labeled using multiplex immunohistochemistry (m-IHC) to decipher the rate and spatial distribution of T cells, B cells, macrophages, and neutrophils in formalin-fixed, paraffin-embedded tumor tissues isolated from these patients. Tumor immune-microenvironmental features and patient survival stratified by CLDN18.2 expression were analyzed using two independent-sample t-tests and log-rank tests, respectively. Results We considered moderate-to-strong CLDN18.2 expression ≥ 40% of tumor cells as the cut-off for positivity. The proportion of CD8+PD-1−, CD8+LAG-3−, and CD8+TIM-3− T cells was significantly higher in CLDN18.2-positive tumors than in negative tumors (0.039 vs. 0.026, P = 0.009; 0.050 vs.0.035, P = 0.024; 0.045 vs. 0.032, P = 0.038, respectively). In addition, the number of neutrophils (CD66b+) was higher in the CLDN18.2-positive group than in the negative group (0.081 vs. 0.055, P = 0.031, respectively), while the rates of M1 (CD68+CD163−HLA-DR+), M2 macrophages (CD68+CD163+HLA-DR−), and B cells (CD20+) were comparable between the CLDN18.2-positive and negative groups. The average numbers of CD8+PD-1−, CD8+LAG-3−, and CD8+TIM-3−T cells surrounding tumor cells within a 20-μm range were higher in CLDN18.2-positive tumors than in the CLDN18.2-negative tumors (0.16 vs. 0.09, P = 0.011; 0.20 vs. 0.12, P = 0.029; 0.18 vs. 0.12, P = 0.047, respectively). In addition, in the CLDN18.2-positive group, tumor cells surrounded by CD8+PD-1−, CD8+LAG-3− T cells, or M1 macrophages within a 20-μm range accounted for a higher proportion of all tumor cells than those in the CLDN18.2-negative group (10.79% vs. 6.60%, P = 0.015; 12.68% vs. 8.70%, P = 0.049; 9.08% vs. 6.56%, P = 0.033, respectively). These findings suggest that CLDN18.2-positive GC harbors complex immune-microenvironmental features. Additionally, CLDN18.2-positive group had shorter OS and irOS than CLDN18.2-negative group (median OS: 23.33 vs.36.6 months, P < 0.001; median irOS: 10.03 vs. 20.13 months, P = 0.044, respectively). Conclusions CLDN18.2-positive GC displayed unique immune-microenvironmental characteristics, which is of great significance for the development of CLDN18.2-targeted therapies. However, the impact of CLDN18.2-related microenvironmental features on prognosis requires further investigation.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cells, cldn, tumor, immune, cancer, expression, pubmed, cldnpositive, article, patients, gastric, cell, google, scholar, normal, microenvironment, tissues, higher, central, study, effective, fig, clinical, cas, table, spatial, advanced, additional, tumors, group, features, file, negative, therapy, tissue, analysis, results, characteristics, positive, cohort, data, claudin, survival, proportion, cldnnegative, based, cart, score, clinicopathological, immunotherapy,

Topics {✒️}

cd4/cd8/cd20/cd66b/cd68/cd163/pd-1/pd-l1/tim-3/lag-3/foxp3/ctla-4/hla-dr/sting $$\mathrm{effective}\ \mathrm{score}=\frac{\mathrm{number}\ \mathrm{ }\ \mathrm{central}\ \mathrm{tumor}\mathrm{ }\ \mathrm{edges}}{\mathrm{number}\ \mathrm{ received anti-pd-1/pd-l1 immunotherapy received anti-pd-1/pd-l1 treatment pd-1/pd-l1 expressing cd8/cd4 cd68+cd163−hla-dr+ cd68+cd163+hla-dr− anti-pd-1/pd-l1 regimens anti-pd-1/pd-l1 immunotherapy anti-pd-1/pd-l1 therapy }\ \mathrm{cells}\ \mathrm{ pd-1/pd-l1-positive lymphocytes advanced gastric/gastro-esophageal junction anti-pd-1/pd-l1 pd-1/pd-l1 icis cd4+foxp3−pd-l1− pd-1/pd-l1 inhibitors antibody-dependent cellular cytotoxicity cancer-related deaths worldwide gastro-oesophageal junction cancer pre-optimized antibody concentration article download pdf epstein-barr-encoded rna 1 nod/scid mice treated pd-l1 cps score 2-positive gastric cancer-specific restore anti-tumor immunity x-young scholars project pd-1/pd-l1 expression mediate cell-cell adhesion cell-mediated cell killing independent sample t-test lei jiao independent-sample t-tests tumor immune-microenvironmental features pan-cancer target suitable single-stained glass slides eosin-stained tissue sections multiplex immunohistochemistry defines heat-induced antigen retrieval tumor-adjacent normal tissues tumor-adjacent normal tissue tumor-infiltrating immune cells log-rank test based tumor-immune cell interaction cd4+pd-l1+ poor/mediate-poor differentiation postdoctoral research foundation

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
         description:The FAST study identified claudin-18 (CLDN18.2) as a promising novel therapeutic target for gastric cancer (GC). However, the tumor immune microenvironment and clinicopathological features of CLDN18.2-positive GC are unclear, making it difficult to develop and optimize CLDN18.2-targeted treatments. This study included 80 GC patients, 60 of whom received anti-PD-1/PD-L1 treatment. CD4/CD8/CD20/CD66b/CD68/CD163/PD-1/PD-L1/TIM-3/LAG-3/FoxP3/CTLA-4/HLA-DR/STING, and CLDN18.2 were labeled using multiplex immunohistochemistry (m-IHC) to decipher the rate and spatial distribution of T cells, B cells, macrophages, and neutrophils in formalin-fixed, paraffin-embedded tumor tissues isolated from these patients. Tumor immune-microenvironmental features and patient survival stratified by CLDN18.2 expression were analyzed using two independent-sample t-tests and log-rank tests, respectively. We considered moderate-to-strong CLDN18.2 expression ≥ 40% of tumor cells as the cut-off for positivity. The proportion of CD8+PD-1−, CD8+LAG-3−, and CD8+TIM-3− T cells was significantly higher in CLDN18.2-positive tumors than in negative tumors (0.039 vs. 0.026, P = 0.009; 0.050 vs.0.035, P = 0.024; 0.045 vs. 0.032, P = 0.038, respectively). In addition, the number of neutrophils (CD66b+) was higher in the CLDN18.2-positive group than in the negative group (0.081 vs. 0.055, P = 0.031, respectively), while the rates of M1 (CD68+CD163−HLA-DR+), M2 macrophages (CD68+CD163+HLA-DR−), and B cells (CD20+) were comparable between the CLDN18.2-positive and negative groups. The average numbers of CD8+PD-1−, CD8+LAG-3−, and CD8+TIM-3−T cells surrounding tumor cells within a 20-μm range were higher in CLDN18.2-positive tumors than in the CLDN18.2-negative tumors (0.16 vs. 0.09, P = 0.011; 0.20 vs. 0.12, P = 0.029; 0.18 vs. 0.12, P = 0.047, respectively). In addition, in the CLDN18.2-positive group, tumor cells surrounded by CD8+PD-1−, CD8+LAG-3− T cells, or M1 macrophages within a 20-μm range accounted for a higher proportion of all tumor cells than those in the CLDN18.2-negative group (10.79% vs. 6.60%, P = 0.015; 12.68% vs. 8.70%, P = 0.049; 9.08% vs. 6.56%, P = 0.033, respectively). These findings suggest that CLDN18.2-positive GC harbors complex immune-microenvironmental features. Additionally, CLDN18.2-positive group had shorter OS and irOS than CLDN18.2-negative group (median OS: 23.33 vs.36.6 months, P < 0.001; median irOS: 10.03 vs. 20.13 months, P = 0.044, respectively). CLDN18.2-positive GC displayed unique immune-microenvironmental characteristics, which is of great significance for the development of CLDN18.2-targeted therapies. However, the impact of CLDN18.2-related microenvironmental features on prognosis requires further investigation.
         datePublished:2022-07-11T00:00:00Z
         dateModified:2023-09-29T00:00:00Z
         pageStart:1
         pageEnd:15
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12916-022-02421-1
         keywords:
            Gastric cancer
            CLDN18.2
            Tumor microenvironment
            Immune cell
            Prognosis
            Medicine/Public Health
            general
            Biomedicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12916-022-02421-1/MediaObjects/12916_2022_2421_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12916-022-02421-1/MediaObjects/12916_2022_2421_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12916-022-02421-1/MediaObjects/12916_2022_2421_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12916-022-02421-1/MediaObjects/12916_2022_2421_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12916-022-02421-1/MediaObjects/12916_2022_2421_Fig5_HTML.png
         isPartOf:
            name:BMC Medicine
            issn:
               1741-7015
            volumeNumber:20
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Keren Jia
               affiliation:
                     name:Peking University Cancer Hospital & Institute
                     address:
                        name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yang Chen
               affiliation:
                     name:Peking University Cancer Hospital & Institute
                     address:
                        name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yu Sun
               affiliation:
                     name:Peking University Cancer Hospital & Institute
                     address:
                        name:Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yajie Hu
               affiliation:
                     name:Peking University Cancer Hospital & Institute
                     address:
                        name:Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lei Jiao
               affiliation:
                     name:Panovue Biotechnology (Beijing) Co., Ltd
                     address:
                        name:Panovue Biotechnology (Beijing) Co., Ltd, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jie Ma
               affiliation:
                     name:Panovue Biotechnology (Beijing) Co., Ltd
                     address:
                        name:Panovue Biotechnology (Beijing) Co., Ltd, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jiajia Yuan
               affiliation:
                     name:Peking University Cancer Hospital & Institute
                     address:
                        name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Changsong Qi
               affiliation:
                     name:Peking University Cancer Hospital & Institute
                     address:
                        name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yanyan Li
               affiliation:
                     name:Peking University Cancer Hospital & Institute
                     address:
                        name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jifang Gong
               affiliation:
                     name:Peking University Cancer Hospital & Institute
                     address:
                        name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jing Gao
               affiliation:
                     name:National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
                     address:
                        name:National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xiaotian Zhang
               affiliation:
                     name:Peking University Cancer Hospital & Institute
                     address:
                        name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jian Li
               affiliation:
                     name:Peking University Cancer Hospital & Institute
                     address:
                        name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Cheng Zhang
               affiliation:
                     name:Peking University Cancer Hospital & Institute
                     address:
                        name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Lin Shen
               affiliation:
                     name:Peking University Cancer Hospital & Institute
                     address:
                        name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
      description:The FAST study identified claudin-18 (CLDN18.2) as a promising novel therapeutic target for gastric cancer (GC). However, the tumor immune microenvironment and clinicopathological features of CLDN18.2-positive GC are unclear, making it difficult to develop and optimize CLDN18.2-targeted treatments. This study included 80 GC patients, 60 of whom received anti-PD-1/PD-L1 treatment. CD4/CD8/CD20/CD66b/CD68/CD163/PD-1/PD-L1/TIM-3/LAG-3/FoxP3/CTLA-4/HLA-DR/STING, and CLDN18.2 were labeled using multiplex immunohistochemistry (m-IHC) to decipher the rate and spatial distribution of T cells, B cells, macrophages, and neutrophils in formalin-fixed, paraffin-embedded tumor tissues isolated from these patients. Tumor immune-microenvironmental features and patient survival stratified by CLDN18.2 expression were analyzed using two independent-sample t-tests and log-rank tests, respectively. We considered moderate-to-strong CLDN18.2 expression ≥ 40% of tumor cells as the cut-off for positivity. The proportion of CD8+PD-1−, CD8+LAG-3−, and CD8+TIM-3− T cells was significantly higher in CLDN18.2-positive tumors than in negative tumors (0.039 vs. 0.026, P = 0.009; 0.050 vs.0.035, P = 0.024; 0.045 vs. 0.032, P = 0.038, respectively). In addition, the number of neutrophils (CD66b+) was higher in the CLDN18.2-positive group than in the negative group (0.081 vs. 0.055, P = 0.031, respectively), while the rates of M1 (CD68+CD163−HLA-DR+), M2 macrophages (CD68+CD163+HLA-DR−), and B cells (CD20+) were comparable between the CLDN18.2-positive and negative groups. The average numbers of CD8+PD-1−, CD8+LAG-3−, and CD8+TIM-3−T cells surrounding tumor cells within a 20-μm range were higher in CLDN18.2-positive tumors than in the CLDN18.2-negative tumors (0.16 vs. 0.09, P = 0.011; 0.20 vs. 0.12, P = 0.029; 0.18 vs. 0.12, P = 0.047, respectively). In addition, in the CLDN18.2-positive group, tumor cells surrounded by CD8+PD-1−, CD8+LAG-3− T cells, or M1 macrophages within a 20-μm range accounted for a higher proportion of all tumor cells than those in the CLDN18.2-negative group (10.79% vs. 6.60%, P = 0.015; 12.68% vs. 8.70%, P = 0.049; 9.08% vs. 6.56%, P = 0.033, respectively). These findings suggest that CLDN18.2-positive GC harbors complex immune-microenvironmental features. Additionally, CLDN18.2-positive group had shorter OS and irOS than CLDN18.2-negative group (median OS: 23.33 vs.36.6 months, P < 0.001; median irOS: 10.03 vs. 20.13 months, P = 0.044, respectively). CLDN18.2-positive GC displayed unique immune-microenvironmental characteristics, which is of great significance for the development of CLDN18.2-targeted therapies. However, the impact of CLDN18.2-related microenvironmental features on prognosis requires further investigation.
      datePublished:2022-07-11T00:00:00Z
      dateModified:2023-09-29T00:00:00Z
      pageStart:1
      pageEnd:15
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12916-022-02421-1
      keywords:
         Gastric cancer
         CLDN18.2
         Tumor microenvironment
         Immune cell
         Prognosis
         Medicine/Public Health
         general
         Biomedicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12916-022-02421-1/MediaObjects/12916_2022_2421_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12916-022-02421-1/MediaObjects/12916_2022_2421_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12916-022-02421-1/MediaObjects/12916_2022_2421_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12916-022-02421-1/MediaObjects/12916_2022_2421_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12916-022-02421-1/MediaObjects/12916_2022_2421_Fig5_HTML.png
      isPartOf:
         name:BMC Medicine
         issn:
            1741-7015
         volumeNumber:20
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Keren Jia
            affiliation:
                  name:Peking University Cancer Hospital & Institute
                  address:
                     name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yang Chen
            affiliation:
                  name:Peking University Cancer Hospital & Institute
                  address:
                     name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yu Sun
            affiliation:
                  name:Peking University Cancer Hospital & Institute
                  address:
                     name:Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yajie Hu
            affiliation:
                  name:Peking University Cancer Hospital & Institute
                  address:
                     name:Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lei Jiao
            affiliation:
                  name:Panovue Biotechnology (Beijing) Co., Ltd
                  address:
                     name:Panovue Biotechnology (Beijing) Co., Ltd, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jie Ma
            affiliation:
                  name:Panovue Biotechnology (Beijing) Co., Ltd
                  address:
                     name:Panovue Biotechnology (Beijing) Co., Ltd, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jiajia Yuan
            affiliation:
                  name:Peking University Cancer Hospital & Institute
                  address:
                     name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Changsong Qi
            affiliation:
                  name:Peking University Cancer Hospital & Institute
                  address:
                     name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yanyan Li
            affiliation:
                  name:Peking University Cancer Hospital & Institute
                  address:
                     name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jifang Gong
            affiliation:
                  name:Peking University Cancer Hospital & Institute
                  address:
                     name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jing Gao
            affiliation:
                  name:National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
                  address:
                     name:National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xiaotian Zhang
            affiliation:
                  name:Peking University Cancer Hospital & Institute
                  address:
                     name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jian Li
            affiliation:
                  name:Peking University Cancer Hospital & Institute
                  address:
                     name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Cheng Zhang
            affiliation:
                  name:Peking University Cancer Hospital & Institute
                  address:
                     name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Lin Shen
            affiliation:
                  name:Peking University Cancer Hospital & Institute
                  address:
                     name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Medicine
      issn:
         1741-7015
      volumeNumber:20
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Peking University Cancer Hospital & Institute
      address:
         name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
         type:PostalAddress
      name:Peking University Cancer Hospital & Institute
      address:
         name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
         type:PostalAddress
      name:Peking University Cancer Hospital & Institute
      address:
         name:Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
         type:PostalAddress
      name:Peking University Cancer Hospital & Institute
      address:
         name:Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
         type:PostalAddress
      name:Panovue Biotechnology (Beijing) Co., Ltd
      address:
         name:Panovue Biotechnology (Beijing) Co., Ltd, Beijing, China
         type:PostalAddress
      name:Panovue Biotechnology (Beijing) Co., Ltd
      address:
         name:Panovue Biotechnology (Beijing) Co., Ltd, Beijing, China
         type:PostalAddress
      name:Peking University Cancer Hospital & Institute
      address:
         name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
         type:PostalAddress
      name:Peking University Cancer Hospital & Institute
      address:
         name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
         type:PostalAddress
      name:Peking University Cancer Hospital & Institute
      address:
         name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
         type:PostalAddress
      name:Peking University Cancer Hospital & Institute
      address:
         name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
         type:PostalAddress
      name:National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
      address:
         name:National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
         type:PostalAddress
      name:Peking University Cancer Hospital & Institute
      address:
         name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
         type:PostalAddress
      name:Peking University Cancer Hospital & Institute
      address:
         name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
         type:PostalAddress
      name:Peking University Cancer Hospital & Institute
      address:
         name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
         type:PostalAddress
      name:Peking University Cancer Hospital & Institute
      address:
         name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Keren Jia
      affiliation:
            name:Peking University Cancer Hospital & Institute
            address:
               name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
               type:PostalAddress
            type:Organization
      name:Yang Chen
      affiliation:
            name:Peking University Cancer Hospital & Institute
            address:
               name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
               type:PostalAddress
            type:Organization
      name:Yu Sun
      affiliation:
            name:Peking University Cancer Hospital & Institute
            address:
               name:Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
               type:PostalAddress
            type:Organization
      name:Yajie Hu
      affiliation:
            name:Peking University Cancer Hospital & Institute
            address:
               name:Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
               type:PostalAddress
            type:Organization
      name:Lei Jiao
      affiliation:
            name:Panovue Biotechnology (Beijing) Co., Ltd
            address:
               name:Panovue Biotechnology (Beijing) Co., Ltd, Beijing, China
               type:PostalAddress
            type:Organization
      name:Jie Ma
      affiliation:
            name:Panovue Biotechnology (Beijing) Co., Ltd
            address:
               name:Panovue Biotechnology (Beijing) Co., Ltd, Beijing, China
               type:PostalAddress
            type:Organization
      name:Jiajia Yuan
      affiliation:
            name:Peking University Cancer Hospital & Institute
            address:
               name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
               type:PostalAddress
            type:Organization
      name:Changsong Qi
      affiliation:
            name:Peking University Cancer Hospital & Institute
            address:
               name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
               type:PostalAddress
            type:Organization
      name:Yanyan Li
      affiliation:
            name:Peking University Cancer Hospital & Institute
            address:
               name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
               type:PostalAddress
            type:Organization
      name:Jifang Gong
      affiliation:
            name:Peking University Cancer Hospital & Institute
            address:
               name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
               type:PostalAddress
            type:Organization
      name:Jing Gao
      affiliation:
            name:National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
            address:
               name:National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
               type:PostalAddress
            type:Organization
      name:Xiaotian Zhang
      affiliation:
            name:Peking University Cancer Hospital & Institute
            address:
               name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
               type:PostalAddress
            type:Organization
      name:Jian Li
      affiliation:
            name:Peking University Cancer Hospital & Institute
            address:
               name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
               type:PostalAddress
            type:Organization
      name:Cheng Zhang
      affiliation:
            name:Peking University Cancer Hospital & Institute
            address:
               name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Lin Shen
      affiliation:
            name:Peking University Cancer Hospital & Institute
            address:
               name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
      name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
      name:Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
      name:Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
      name:Panovue Biotechnology (Beijing) Co., Ltd, Beijing, China
      name:Panovue Biotechnology (Beijing) Co., Ltd, Beijing, China
      name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
      name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
      name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
      name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
      name:National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
      name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
      name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
      name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
      name:Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

External Links {🔗}(199)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.81s.

LINK . SPRINGER . COM {}